Search

Displaying results 811 - 820 of 6183 in total
  1. Drug

    Cupric sulfate

    go.drugbank.com/drugs/DB06778
    Approved

    Cupric sulfate is used primarily for agricultural purposes, as a pesticide, germicide, feed additive, and soil additive. … Copper is a component of intrauterine contraceptive devices (IUD) and the release of copper is necessary for their important contraceptive effects.

    Mixtures: Se-Tan PLUS
  2. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … [A189006,A189030] Whereas historically popular pharmacologic treatments for insomnia (e.g.

    Categories: Orexin Receptor Antagonists
  3. Drug

    Vitamin A

    go.drugbank.com/drugs/DB00162
    ApprovedInvestigationalNutraceuticalVet approved

    Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A i...

    Mixtures: For-2, TAMIPOOL FOR INJECTIONCategories: Tests for Fat Absorption, Anti-Acne Preparations for Topical Use
  4. Drug

    Pioglitazone

    go.drugbank.com/drugs/DB01132
    ApprovedInvestigational

    [A19759] Thiazolidinediones, including pioglitazone, have fallen out of favor in recent years due to the presence of multiple adverse effects and warnings regarding their use (e.g. congestive heart … failure, bladder cancer) and the availability of safer and more effective alternatives for patients with type 2 diabetes mellitus.

    Categories: Peroxisome Proliferator Receptor gamma Agonist, Peroxisome Proliferator-activated Receptor Activity
  5. Drug

    Atoltivimab

    go.drugbank.com/drugs/DB15898
    ApprovedInvestigational

    [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … Ebola virus (EBOV) remains an important human pathogen within the _Ebolavirus_ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.

    Categories: Treatments for Ebola Virus Disease
  6. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.

    Mixtures: Se-Tan DHA, Se-Tan DHA
  7. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    and for radiolabeling Zevalin (ibritumomab tiuxetan) in preparations used for radioimmunotherapy procedures. … Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for _in vivo_ diagnostic imaging procedures

    Mixtures: OCTREOSCAN FOR INJECTION, Kit for the Preparation of Indium In 111 Pentetreotide
  8. Drug

    Vitamin E

    go.drugbank.com/drugs/DB00163
    ApprovedInvestigationalNutraceuticalVet approved

    Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. … The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory

    Mixtures: For-2, Multi-force for Women Tab
  9. Drug

    Manganese cation

    go.drugbank.com/drugs/DB06757
    ApprovedInvestigationalNutraceutical

    [A263687, A263662] In humans, manganese regulates several physiological processes by acting as a cofactor for proteins [A263657, A263662, A263667] making it an essential metal for normal development and

    Mixtures: Se-Tan PLUS, For-2
  10. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic … [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment

    Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors, Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors